previous studies in our laboratory have shown that the reported antitumor activity of systemically administered swainsonine , an indolizidine alkaloid , is due at least in part to immune modulation involving effector cells ( humphries , m.j. ;
C0085535
swainsonine
C0002062
alkaloid